Tibolone Dosage and Contraindications for Hormone Replacement Therapy

Introduction to Tibolone

The American College of Oncology recommends a dosage of 2.5 mg daily for tibolone in hormone replacement therapy, with 1.25 mg daily as an alternative lower dose option that may have similar efficacy with potentially better tolerability 1

The standard therapeutic dose of tibolone is 2.5 mg daily, which effectively reduces menopausal symptoms including hot flashes, sweating episodes, and vaginal dryness 1
Tibolone should be administered continuously without interruptions when used for hormone replacement therapy 2

Tibolone is a synthetic compound with weak estrogenic, progestogenic, and androgenic actions 1
It effectively reduces hot flashes and improves vaginal dryness in postmenopausal women 1
Tibolone may improve sexual function more effectively than standard hormone therapy 1
In the breast, tibolone inhibits the enzyme sulfatase, which regulates estrogen formation and decreases estrogen stimulation 1
Studies show tibolone causes less breast tenderness and mammographic density changes compared to conventional hormone replacement therapy 1

Breast cancer history is a major contraindication for tibolone use, as recommended by the American College of Oncology and Praxis Medical Insights 1, 3
A large prospective, randomized, placebo-controlled trial (LIBERATE) was halted due to safety concerns when tibolone was used in breast cancer survivors 1
Tibolone should not be used in patients with known or suspected estrogen-dependent malignant tumors, as stated by Praxis Medical Insights 3
Tibolone is also contraindicated in patients with undiagnosed vaginal bleeding, untreated endometrial hyperplasia, previous or current venous thromboembolic disorders, known thrombophilic disorders, active or recent arterial thromboembolic disease, acute liver disease, or history of liver disease where liver function tests have not returned to normal, and porphyria, according to Praxis Medical Insights 3

HRT should generally be continued until the average age of spontaneous menopause (45-55 years), as recommended by Blood Reviews 2
After menopause age, decisions about continuation should be based on individual risks, family history, and symptom severity, according to Praxis Medical Insights 3

Weight gain, acne, and hirsutism (due to androgenic effects) are common side effects of tibolone, as reported by Clinical Reviews in Allergy and Immunology 4
Mood changes are also a common side effect of tibolone, as stated by Praxis Medical Insights 5

Tibolone 2.5 mg daily significantly reduces vasomotor (hot‑flush) symptoms (odds ratio 0.33, 95 % CI 0.27–0.41) and provides greater improvement in vaginal dryness, sexual function, and mood compared with standard hormone therapy; evidence derives from randomized controlled trials of moderate to high quality【6】【7】.

In women with a prior history of breast cancer, tibolone markedly increases tumor recurrence (odds ratio 1.50, 95 % CI 1.21–1.85) as demonstrated in the LIBERATE trial, which was stopped early because of safety concerns; this finding is based on high‑quality RCT data【6】【7】.
Breast tenderness occurs far less frequently with tibolone than with conventional hormone‑replacement therapy, indicating a more favorable breast‑related side‑effect profile; this observation comes from pooled trial data of moderate quality【6】【7】.
Consequently, tibolone is an absolute contraindication for any woman with known or suspected breast cancer, a recommendation supported by strong clinical trial evidence【6】【7】.

Among women older than 60 years, tibolone use is associated with a doubled risk of stroke (odds ratio 2.18, 95 % CI 1.12–4.21); this result originates from an osteoporosis trial that was terminated early due to safety signals, representing high‑quality evidence【6】【7】.

Tibolone does not increase mammographic breast density, distinguishing it from combined estrogen‑progestogen therapy; this conclusion is based on controlled imaging studies of moderate quality【6】【7】.